| # | Title | Journal | Year | Citations |
|---|
| 1 | The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin | Clinical Infectious Diseases | 2006 | 610 |
| 2 | Diabetes and Risk of Surgical Site Infection: A Systematic Review and Meta-analysis | Infection Control and Hospital Epidemiology | 2016 | 378 |
| 3 | Pertussis: Microbiology, Disease, Treatment, and Prevention | Clinical Microbiology Reviews | 2016 | 301 |
| 4 | American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients | Blood Advances | 2019 | 299 |
| 5 | Evaluation of a Pharmaceutical Care Model on Diabetes Management | Annals of Pharmacotherapy | 1996 | 285 |
| 6 | Recent Advances: the Cytochrome P450 Enzymes | Annals of Pharmacotherapy | 1995 | 238 |
| 7 | Remdesivir: Review of Pharmacology, Pre‐clinical Data, and Emerging Clinical Experience for COVID‐19 | Pharmacotherapy | 2020 | 197 |
| 8 | Dynamic functional connectivity of neurocognitive networks in children | Human Brain Mapping | 2017 | 183 |
| 9 | Ceragenins: Cholic Acid-Based Mimics of Antimicrobial Peptides | Accounts of Chemical Research | 2008 | 182 |
| 10 | A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity | Antimicrobial Agents and Chemotherapy | 2017 | 178 |
| 11 | Multiple versus single virus respiratory infections: viral load and clinical disease severity in hospitalized children | Influenza and Other Respiratory Viruses | 2012 | 175 |
| 12 | The β‐Lactams Strike Back: Ceftazidime‐Avibactam | Pharmacotherapy | 2015 | 160 |
| 13 | Tigecycline: First of a New Class of Antimicrobial Agents | Pharmacotherapy | 2006 | 150 |
| 14 | A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis | Clinical Infectious Diseases | 2018 | 150 |
| 15 | Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists | Clinical Infectious Diseases | 2020 | 142 |
| 16 | Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice | Drug Metabolism and Disposition | 1996 | 142 |
| 17 | Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007) | Journal of Clinical Microbiology | 2008 | 132 |
| 18 | Vancomycin Pharmacokinetics in a Patient Population | Therapeutic Drug Monitoring | 1994 | 127 |
| 19 | The Prevalence of the Metabolic Syndrome Among Arab Americans | Diabetes Care | 2004 | 126 |
| 20 | High‐Dose Daptomycin for Treatment of Complicated Gram‐Positive Infections: A Large, Multicenter, Retrospective Study | Pharmacotherapy | 2011 | 124 |
| 21 | Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus | Journal of Antimicrobial Chemotherapy | 2006 | 121 |
| 22 | Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy | Drug and Alcohol Dependence | 2014 | 121 |
| 23 | Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model | Antimicrobial Agents and Chemotherapy | 2013 | 118 |
| 24 | Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis | Expert Review of Clinical Pharmacology | 2012 | 116 |
| 25 | Diabetes Medications Related to an Increased Risk of Falls and Fall-Related Morbidity in the Elderly | Annals of Pharmacotherapy | 2010 | 115 |
| 26 | Serum 25-Hydroxy Vitamin D and Insulin Resistance, Metabolic Syndrome, and Glucose Intolerance Among Arab Americans | Diabetes Care | 2010 | 113 |
| 27 | Epidemiology of Multiple Respiratory Viruses in Childcare Attendees | Journal of Infectious Diseases | 2013 | 107 |
| 28 | Epidemiology of Diabetes Among Arab Americans | Diabetes Care | 2003 | 106 |
| 29 | Short-Course Gentamicin in Combination with Daptomycin or Vancomycin against Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations | Antimicrobial Agents and Chemotherapy | 2005 | 106 |
| 30 | Antimicrobial Activities of Ceragenins against Clinical Isolates of Resistant Staphylococcus aureus | Antimicrobial Agents and Chemotherapy | 2007 | 106 |
| 31 | Pharmacokinetics and Pharmacodynamics of Cefepime in Patients with Various Degrees of Renal Function | Antimicrobial Agents and Chemotherapy | 2003 | 104 |
| 32 | Community-Associated Methicillin-ResistantStaphylococcus aureus: A Review | Pharmacotherapy | 2005 | 104 |
| 33 | Evaluation of Accessory Gene Regulator ( agr ) Group and Function in the Proclivity towards Vancomycin Intermediate Resistance in Staphylococcus aureus | Antimicrobial Agents and Chemotherapy | 2007 | 101 |
| 34 | Perils and pitfalls of long-term effects of proton pump inhibitors | Expert Review of Clinical Pharmacology | 2013 | 101 |
| 35 | Characteristics of Patients With Healthcare-Associated Infection Due to SCCmecType IV Methicillin-ResistantStaphylococcus aureus | Infection Control and Hospital Epidemiology | 2006 | 100 |
| 36 | Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections | Clinical Infectious Diseases | 2016 | 99 |
| 37 | Lack of Acculturation Is a Risk Factor for Diabetes in Arab Immigrants in the U.S. | Diabetes Care | 2003 | 98 |
| 38 | Trough concentrations of cyclosporine in blood following administration with grapefruit juice | British Journal of Clinical Pharmacology | 1993 | 96 |
| 39 | Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin | Antimicrobial Agents and Chemotherapy | 2018 | 96 |
| 40 | Daptomycin | Pharmacotherapy | 2004 | 95 |
| 41 | Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms | Antimicrobial Agents and Chemotherapy | 2003 | 94 |
| 42 | Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents | Diagnostic Microbiology and Infectious Disease | 2007 | 94 |
| 43 | Influences of Linezolid, Penicillin, and Clindamycin, Alone and in Combination, on Streptococcal Pyrogenic Exotoxin A Release | Antimicrobial Agents and Chemotherapy | 2003 | 91 |
| 44 | A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis | Journal of Antimicrobial Chemotherapy | 2013 | 90 |
| 45 | Evaluation of Daptomycin Pharmacodynamics and Resistance at Various Dosage Regimens against Staphylococcus aureus Isolates with Reduced Susceptibilities to Daptomycin in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations | Antimicrobial Agents and Chemotherapy | 2008 | 89 |
| 46 | Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa | Journal of Antimicrobial Chemotherapy | 2007 | 87 |
| 47 | A pilot randomized clinical trial of an intervention to reduce overdose risk behaviors among emergency department patients at risk for prescription opioid overdose | Drug and Alcohol Dependence | 2016 | 87 |
| 48 | The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials | Pharmacotherapy | 1998 | 87 |
| 49 | The triazole antifungal agents: a review of itraconazole and fluconazole | Pharmacotherapy | 1990 | 86 |
| 50 | Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections | Open Forum Infectious Diseases | 2019 | 85 |
